If you are currently taking a compounded version, considering one, or trying to make sense of the warnings you've been seeing, this guide explains exactly where things stand right now and what the actual risks look like
There is little clinical evidence for these transdermal herbal patches as GLP-1 therapies
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
The future of the GLP-1 receptor agonists
This challenge is why some scientists question whether oral GLP-1 drugs can be as potent as injectables, Cavender says
Back Gilbert, B, Rosenthal, D (5 March 2024) 'The Scientific Journey Behind Ozempic (with Lotte Bjerre Knudsen, Novo Nordisk's Chief Scientific Advisor)', Acquired podcast, ACQ2 Episode